IMRX

SEC source: 0001790340-26-000082 · wk-form4_1784320143.xml · derivative · entry 1

Gengos Andrew · CIK 0001563623 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Class A Common Stock · 650,000 shares

Expires 2036-07-16

F1 · derivative.exercise_date: Subject to the reporting person's continued employment through each applicable vesting date, 8.33333% of the shares underlying the stock option shall vest on each of the first, second and third monthly anniversary of the grant transaction date (the "Grant Date"); 1.6667% of the shares underlying the stock option shall vest on the fourth monthly anniversary of the Grant Date and on each monthly anniversary thereafter until the one year anniversary of the Grant Date; 3.33333% of the shares underlying the stock option shall vest on each monthly anniversary following the one-year anniversary of the Grant Date until the second anniversary of the Grant Date; and 0.833333% of the of the shares underlying the stock option shall vest on each monthly anniversary following the second anniversary of the Grant Date until the fourth anniversary of the Grant Date, such that all shares underlying the stock option shall be fully vested on the fourth anniversary of the Grant Date.

SEC source: 0001790340-26-000078 · wk-form4_1782331885.xml · nonDerivative · entry 1

Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,315,252

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-26-000076 · wk-form4_1781640910.xml · nonDerivative · entry 1

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 382,531

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.146 to $4.15. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-26-000068 · wk-form4_1781213381.xml · derivative · entry 1

CARPENTER ROBERT J · CIK 0001021046 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000064 · wk-form4_1781213003.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000066 · wk-form4_1781213173.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000072 · wk-form4_1781213861.xml · derivative · entry 1

Schall Thomas J. · CIK 0001423084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000070 · wk-form4_1781213596.xml · derivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2036-06-11

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-26-000044 · wk-form4_1773780394.xml · nonDerivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,598

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 16, 2025 through March 15, 2026. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

F2 · date: The relevant Offering Period (as defined in the ESPP) ended on March 15, 2026. The shares were acquired on the Purchase Date (as defined in the ESPP) of March 13, 2026.

F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of the relevant Offering Period.

SEC source: 0001790340-26-000022 · wk-form4_1770297015.xml · derivative · entry 1

Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 688,000

Underlying: Class A Common Stock · 688,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000028 · wk-form4_1770298047.xml · derivative · entry 1

Matushansky Igor · CIK 0001768208 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Class A Common Stock · 140,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000034 · wk-form4_1770299088.xml · derivative · entry 1

Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,000

Underlying: Class A Common Stock · 176,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000032 · wk-form4_1770298673.xml · derivative · entry 1

Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Class A Common Stock · 140,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000030 · wk-form4_1770298352.xml · derivative · entry 1

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 344,000

Underlying: Class A Common Stock · 344,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000026 · wk-form4_1770297748.xml · derivative · entry 1

Morales Mallory · CIK 0001941795 · SVP Finance, CAO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Class A Common Stock · 140,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000024 · wk-form4_1770297286.xml · derivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Class A Common Stock · 140,000 shares

Expires 2036-02-03

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

SEC source: 0001790340-26-000016 · wk-form4_1769004593.xml · nonDerivative · entry 1

Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,050

SEC source: 0001790340-26-000012 · wk-form4_1768597660.xml · nonDerivative · entry 1

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,496

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.57 to $4.571. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-26-000014 · wk-form4_1768918646.xml · nonDerivative · entry 1

Schall Thomas J. · CIK 0001423084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,530

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.61 to $4.69. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-26-000010 · wk-form4_1768482368.xml · nonDerivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,970

SEC source: 0001790340-26-000008 · wk-form4_1768396231.xml · nonDerivative · entry 4

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · General Partner of S4K Investments LLC.

Disclosed balance after: 135,441

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-26-000002 · wk-form4_1767390602.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,888

Underlying: Class A Common Stock · 7,888 shares

Expires 2036-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

SEC source: 0001790340-26-000004 · wk-form4_1767390971.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,888

Underlying: Class A Common Stock · 7,888 shares

Expires 2036-01-01

F1 · security: Pursuant to the Immuneering Corporation Non-Employee Director Compensation Program (the "Compensation Program"), the reporting person elected to receive this stock option in lieu of receiving the cash Base Retainer (as defined in the Compensation Program).

F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the shares subject to the option upon the reporting person completing three months of continuous service as a Non-Employee Director (as defined in the Compensation Program) following the grant date, such that the fourth and final installment will vest and become exercisable on the first anniversary of the grant date, subject in each case to such continuous service.

SEC source: 0001790340-25-000127 · wk-form4_1759841769.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,766

SEC source: 0001790340-25-000123 · wk-form4_1759409848.xml · nonDerivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,344

SEC source: 0001790340-25-000125 · wk-form4_1759410175.xml · nonDerivative · entry 1

Morales Mallory · CIK 0001941795 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,533

SEC source: 0001790340-25-000121 · wk-form4_1759409561.xml · nonDerivative · entry 1

Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,870

SEC source: 0001790340-25-000119 · wk-form4_1759323577.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,266

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.0049 to $7.055. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000117 · wk-form4_1759237255.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,766

SEC source: 0001790340-25-000115 · wk-form4_1758141678.xml · nonDerivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,544

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025.

F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period.

SEC source: 0001790340-25-000113 · wk-form4_1758141356.xml · nonDerivative · entry 1

Morales Mallory · CIK 0001941795 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,233

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025.

F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period.

SEC source: 0001790340-25-000111 · wk-form4_1758141012.xml · nonDerivative · entry 1

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,198

F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934.

F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025.

F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period.

SEC source: 0001790340-25-000094 · wk-form4_1751548321.xml · nonDerivative · entry 2

Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,312,852

F2 · balance_after: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.45 to $3.64. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000098 · wk-form4_1751893158.xml · nonDerivative · entry 2

HAUSMAN DIANA · CIK 0001563992 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 3,000

SEC source: 0001790340-25-000098 · wk-form4_1751893158.xml · nonDerivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,500

SEC source: 0001790340-25-000096 · wk-form4_1751892717.xml · nonDerivative · entry 1

Neufeld Leah R · CIK 0001950673 · CHIEF PEOPLE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,729

SEC source: 0001790340-25-000094 · wk-form4_1751548321.xml · nonDerivative · entry 1

Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,305,837

F1 · balance_after: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.35 to $3.41. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000089 · wk-form4_1751288953.xml · nonDerivative · entry 1

Schall Thomas J. · CIK 0001423084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,885

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $3.6 to $3.73. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000087 · wk-form4_1750770096.xml · nonDerivative · entry 2

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 359,318

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.4101 to $2.4299. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000085 · wk-form4_1750769533.xml · nonDerivative · entry 1

Brakewood Harold Eugene · CIK 0001969578 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,800

SEC source: 0001790340-25-000087 · wk-form4_1750770096.xml · nonDerivative · entry 1

Hall Brett Matthew · CIK 0001870437 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353,311

SEC source: 0001790340-25-000081 · wk-form4_1750424967.xml · nonDerivative · entry 1

Zeskind Benjamin J. · CIK 0001870062 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,302,852

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.31 to $2.44. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000083 · wk-form4_1750684190.xml · nonDerivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,766

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.07 to $2.96. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000079 · wk-form4_1750252275.xml · nonDerivative · entry 1

Schall Thomas J. · CIK 0001423084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,385

F1 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.16 to $2.24. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

SEC source: 0001790340-25-000067 · wk-form4_1750078761.xml · derivative · entry 1

CARPENTER ROBERT J · CIK 0001021046 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-25-000069 · wk-form4_1750079056.xml · derivative · entry 1

Feinberg Peter · CIK 0001870076 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-25-000071 · wk-form4_1750079353.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-25-000073 · wk-form4_1750079729.xml · derivative · entry 1

Schall Thomas J. · CIK 0001423084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-25-000065 · wk-form4_1750078473.xml · derivative · entry 1

BERMAN ANN E · CIK 0001349408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.

SEC source: 0001790340-25-000075 · wk-form4_1750080081.xml · derivative · entry 1

HAUSMAN DIANA · CIK 0001563992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,350

Underlying: Class A Common Stock · 33,350 shares

Expires 2035-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.